Back from ASH 2025, Dr Suchitra Sundaram reports on notable frontline CLL data. Time‑limited pirtobrutinib combined with venetoclax and obinutuzumab produced high rates of undetectable minimal ...
Triplet therapy with pirtobrutinib, venetoclax and rituximab as a two-year fixed-duration therapy improves progression-free survival for patients with relapsed/refractory chronic lymphocytic leukemia ...
Inflammation is a natural bodily process. It’s a defense system tool used by the body to fight off infections and heal injuries. Think of a time when you’ve cut a finger, for example, or scraped an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results